Alumis Inc. (ALMS:NASDAQ) closed at $6.31 on October 15, 2026, up 4.13% on the day. The stock trades 79.9% below its 52-week high of $31.35 and 44.4% above its 52-week low of $4.37. Over the past year, it gained 36.9%. Alumis Inc. is part of the Health Care sector.
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| -10.62% | -20.53% | -77.45% | -74.46% | +36.88% |
In 252 trading sessions since October 15, 2025, ALMS closed higher on 124 days (49%). Its best day was January 6, 2026 (+95.31%) and its worst was September 1, 2026 (-56.58%). The stock moved 10% or more in a single session 8 times. It opened at least 5% above the previous day's high 2 times.
Alumis' mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis, and is currently being evaluated in additional Phase 2 clinical trials in patients with systemic lupus erythematosus (SLE) and non-infectious uveitis, for which we expect to report results in 2026 and by the end of 2024, respectively.
Find more stocks like ALMS with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.